Warfarin-associated intracerebral hemorrhage

Anna Cavallini, Simona Fanucchi, Alessandra Persico

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Intracerebral hemorrhage (ICH) is the most serious complication of oral anticoagulant therapy (OAT), with mortality in excess of 50%. Major risk factors are advanced patient age, elevated systolic blood pressure, intensity of anticoagulation, and previous cerebral ischemia. A number of acute treatments are available, but all have significant side effects and no randomized clinical trials assessing clinical outcome have been performed. Future trials will have to address choice and dose of agent, the timing of its administration, and the risk of side effects.

Original languageEnglish
JournalNeurological Sciences
Volume29
Issue numberSUPPL. 2
DOIs
Publication statusPublished - Sep 2008

Fingerprint

Cerebral Hemorrhage
Warfarin
Blood Pressure
Brain Ischemia
Anticoagulants
Randomized Controlled Trials
Mortality
Therapeutics

Keywords

  • Epidemiology
  • Intracerebral hemorrhage
  • Treatment
  • Warfarin

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology

Cite this

Warfarin-associated intracerebral hemorrhage. / Cavallini, Anna; Fanucchi, Simona; Persico, Alessandra.

In: Neurological Sciences, Vol. 29, No. SUPPL. 2, 09.2008.

Research output: Contribution to journalArticle

Cavallini, Anna ; Fanucchi, Simona ; Persico, Alessandra. / Warfarin-associated intracerebral hemorrhage. In: Neurological Sciences. 2008 ; Vol. 29, No. SUPPL. 2.
@article{66220e0472e64383bec9e11370286968,
title = "Warfarin-associated intracerebral hemorrhage",
abstract = "Intracerebral hemorrhage (ICH) is the most serious complication of oral anticoagulant therapy (OAT), with mortality in excess of 50{\%}. Major risk factors are advanced patient age, elevated systolic blood pressure, intensity of anticoagulation, and previous cerebral ischemia. A number of acute treatments are available, but all have significant side effects and no randomized clinical trials assessing clinical outcome have been performed. Future trials will have to address choice and dose of agent, the timing of its administration, and the risk of side effects.",
keywords = "Epidemiology, Intracerebral hemorrhage, Treatment, Warfarin",
author = "Anna Cavallini and Simona Fanucchi and Alessandra Persico",
year = "2008",
month = "9",
doi = "10.1007/s10072-008-0959-5",
language = "English",
volume = "29",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Warfarin-associated intracerebral hemorrhage

AU - Cavallini, Anna

AU - Fanucchi, Simona

AU - Persico, Alessandra

PY - 2008/9

Y1 - 2008/9

N2 - Intracerebral hemorrhage (ICH) is the most serious complication of oral anticoagulant therapy (OAT), with mortality in excess of 50%. Major risk factors are advanced patient age, elevated systolic blood pressure, intensity of anticoagulation, and previous cerebral ischemia. A number of acute treatments are available, but all have significant side effects and no randomized clinical trials assessing clinical outcome have been performed. Future trials will have to address choice and dose of agent, the timing of its administration, and the risk of side effects.

AB - Intracerebral hemorrhage (ICH) is the most serious complication of oral anticoagulant therapy (OAT), with mortality in excess of 50%. Major risk factors are advanced patient age, elevated systolic blood pressure, intensity of anticoagulation, and previous cerebral ischemia. A number of acute treatments are available, but all have significant side effects and no randomized clinical trials assessing clinical outcome have been performed. Future trials will have to address choice and dose of agent, the timing of its administration, and the risk of side effects.

KW - Epidemiology

KW - Intracerebral hemorrhage

KW - Treatment

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=53649095042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53649095042&partnerID=8YFLogxK

U2 - 10.1007/s10072-008-0959-5

DO - 10.1007/s10072-008-0959-5

M3 - Article

C2 - 18690514

AN - SCOPUS:53649095042

VL - 29

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - SUPPL. 2

ER -